Antibodies against CD5L for therapeutic and diagnostic uses

Description:

Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

UTHealth Ref. No.: 2020-0016

Inventors: Dr. Zhiqiang An and Dr. Ningyan Zhang at UTHealth; Dr. Anil Sood at UT M.D. Anderson Cancer Center

Patent Status:  PCT application PCT/US2021/025429 filed 4/1/2021; nationalized in US, CN, and EPO

License Available: world-wide, exclusive

 

Patent Information:
For Information, Contact:
Christine Weaver
Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Christine.Weaver@uth.tmc.edu
Inventors:
Zhiqiang An
Ningyan Zhang
Anil Sood
Keywords: